Article
Management of Refractory Malignancy-Associated Hemophagocytic Lymphohistiocytosis in Pediatric Patients: A Case Series of Novel Therapeutics and Treatment Challenges
2025-01-04
Abstract excerpt
Hemophagocytic lymphohistiocytosis (HLH) is a potentially fatal syndrome of immune dysregulation that has primary and secondary forms. HLH is classified based on underlying triggers of malignancy, infections, and/or autoimmune processes. Primary-HLH has a genetic etiology related to defects in cytotoxic T and NK cells. The established standard of care is dexamethasone and etoposide but no guidelines exist for refr...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- dd7d51ac-0d00-5943-a86b-d3a27fde8215
- DOI
- 10.22541/au.173599410.06496449/v1
